最新ニュース Amcor (NYSE:AMCR) 株価情報

Amcor

Amcor is a global producer of plastic packaging primarily for the fast-moving consumer goods industry. About 90% of earnings are exposed to the flexible packaging business. This is soft disposable plastic for a variety of food, drink, healthcare, and hygiene products. The remainder of earnings are from the Latin and North American rigids business, which is primarily beverage bottling for the soft drink industry. Operating in more than 35 countries, Amcor has market share in its established regions of North America, Latin America, Europe, and Asia-Pacific. About half of group sales are derived from North America and the remainder is split equally between Western Europe and emerging markets. Australia and New Zealand sales make up less than 5% of group sales.

Amcor PLC

Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.52) by 23.08 percent. This is a 81.9 percent increase over losses of $(2.21) per share from the same period last year.

Earnings

Earnings Beats

News

ORKA

Oruka Therapeutics Q1 EPS $(0.40) Beats $(0.52) Estimate

Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $(1.74) by 595.4 percent.

Earnings Misses

JBIO

Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate

Contango Ore (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTGO#AMEX">CTGO</a>) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.21) by 795.24 percent. This is a 12.15 percent increase over losses of $(2.14) per share from the same period last year.

CTGO

Contango Ore Q1 EPS $(1.88) Misses $(0.21) Estimate

Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) reported quarterly losses of $(0.71) per share. This is a 29.09 percent decrease over losses of $(0.55) per share from the same period last year.

AARD

Aardvark Therapeutics Q1 EPS $(0.71) Down From $(0.55) YoY

Enpro Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) today announced the pricing of its previously announced offering of senior notes due 2033 (the "Senior Notes"). The face value of the Senior Notes is $450 million with an annual interest rate of 6.125%. The Senior Notes were priced at 100.0% of the face value. The offer was made in the United States to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in reliance on Regulation S under the Securities Act. The Senior Notes offering is expected to close on May 29, 2025.
Enpro intends to use the net proceeds from the offering to fund the redemption of all of its outstanding 5.75% senior notes due 2026 (the "Outstanding Notes"), to repay a portion of the borrowings under its senior secured revolving credit facility used to fund the repayment on April 9, 2025 of all of its then-outstanding term loans under its senior secured credit facility, and to pay fees and expenses in connection with the offering. The conditional redemption of the Outstanding Notes was announced by Enpro on May 13, 2025.

Offerings

Enpro Inc. Prices Offering Of $450M 6.125% Senior Notes Due 2033

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(1.22) per share. This is a 86.75 percent increase over losses of $(9.21) per share from the same period last year.

ENVB

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Empire Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EP#AMEX">EP</a>) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year. The company reported $9.00 million in sales this quarter. This is a 4.10 percent decrease over sales of $9.39 million the same period last year.

Empire Petroleum Q1 Adj. EPS $(0.13) Up From $(0.15) YoY, Sales $9.00M Down From $9.39M YoY

Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) sees Q2 sales of $1.500 million-$1.700 million vs $1.52 million analyst estimate.

Guidance

BZAI

Blaize Holdings Sees Q2 Sales $1.500M-$1.700M vs $1.52M Est

Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) affirms FY2025 sales outlook from $19.00 million-$50.00 million to $19.00 million-$50.00 million.

Blaize Holdings Affirms FY2025 Sales Guidance of $19.00M-$50.00M

MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29.41 percent. This is a 72.73 percent increase over losses of $(1.32) per share from the same period last year.

MTVA

MetaVia Q1 EPS $(0.36) Beats $(0.51) Estimate

Boxlight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) reported quarterly losses of $(1.41) per share. This is a 62.89 percent increase over losses of $(3.80) per share from the same period last year. The company reported $22.40 million in sales this quarter. This is a 39.61 percent decrease over sales of $37.09 million the same period last year.

BOXL

Boxlight Q1 EPS $(1.41) Up From $(3.80) YoY, Sales $22.40M Down From $37.09M YoY

Vroom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) reported quarterly losses of $(1.23) per share. This is a 96.74 percent increase over losses of $(37.68) per share from the same period last year. The company reported $36.20 million in sales this quarter. This is a 3.78 percent increase over sales of $34.88 million the same period last year.

Vroom Q1 EPS $(1.23) Up From $(37.68) YoY, Sales $36.20M Up From $34.88M YoY

CSWC

CORRECTION: Capital Southwest Q4 EPS $0.54 Misses $0.62 Estimate, Sales $52.41M Miss $52.71M Estimate

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) is looking for FY2026 Adj EPS of $9.90-$10.15 vs $9.87 analyst estimate..

Steris Sees FY2026 expects reported revenue from continuing operations to increase 6-7%.

Castor Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) reported quarterly losses of $(1.24) per share. This is a 212.73 percent decrease over earnings of $1.10 per share from the same period last year. The company reported $16.16 million in sales this quarter. This is a 38.69 percent decrease over sales of $26.36 million the same period last year.

CTRM

Castor Maritime Q4 EPS $(1.24) Down From $1.10 YoY, Sales $16.16M Down From $26.36M YoY

Red Cat Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a rundown of the <a href="https://www.benzinga.com/pressreleases/25/05/g45419266/red-cat-reports-financial-results-for-first-quarter-2025-and-provides-corporate-update">drone technology company&#8217;s report</a>.
Q1 Earnings: Red Cat reported first-quarter revenue of $1.63 million, missing <a href="https://www.benzinga.com/quote/rcat/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a> of $3.85 million. The company reported a first-quarter loss of 27 cents per share, missing analyst estimates for a loss of eight cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Red Cat said it expects its partnership with Palantir Technologies will reduce costs and improve margins moving forward.
Red Cat ended the first quarter with $9.3 million in cash and accounts receivable. The company noted that it also closed on $30 million of funding subsequent to the quarter&#8217;s end.
&#8220;Red Cat&#8217;s momentum continues to build as we execute on our strategy to deliver advanced, AI-enabled unmanned systems across air, land, and sea,&#8221; said&nbsp;Jeff Thompson, CEO of Red Cat.
&#8220;Our partnership with Palantir to deploy Warp Speed is optimizing our manufacturing and cost efficiency, while our expansion into maritime autonomy with Unmanned Surface Vessels significantly expands our Family of Systems.&#8221;
Guidance: Red Cat affirmed its full-year 2025 revenue guidance of $80 million to $120 million versus estimates of $80.17 million. Here&#8217;s a breakdown of guidance by category:
<ul class="wp-block-list">
<li>SRR-related Black Widow revenue: $25 to $65 million</li>
</ul>
<ul class="wp-block-list">
<li>Non-SRR Black Widow revenue: $25 million</li>
</ul>
<ul class="wp-block-list">
<li>Edge 130 revenue: $25 million</li>
</ul>
<ul class="wp-block-list">
<li>Fang FPV revenue: $5 million</li>
</ul>
Red Cat executives will further discuss details from the quarter on a call with investors and analysts at 4:30 p.m. ET.
RCAT Price Action: <a href="http://benzinga.com/quote/rcat" target="_blank" rel="noreferrer noopener">Red Cat Holdings shares</a> were down 5.26% in after-hours, trading at $6.30 at the time of publication on Wednesday, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45408452/stock-of-the-day-palantir-breaks-out-sell-news-rally">Stock Of The Day: Palantir Breaks Out As Classic &#8216;Sell the News&#8217; Sets Up Rally</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/MacroEcon">MacroEcon</a>/Shutterstock.

After-Hours Center

Movers

RCAT

Red Cat Holdings Q1 Earnings: Revenue, EPS Miss Estimates, Drone Maker Affirms FY25 Guidance, Highlights Palantir Partnership, Shares Slide

WIIM

USIO

Usio shares are trading lower after the company reported mixed Q1 financial results.

Edesa Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDSA#NASDAQ">EDSA</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 48.28 percent increase over losses of $(0.58) per share from the same period last year.

EDSA

Edesa Biotech Q2 EPS $(0.30) Misses $(0.29) Estimate

SILO

Silo Pharma shares are trading lower. The company announced  it has engaged Veloxity Labs for bioanalysis supporting the ongoing investigational new drug-enabling GLP-compliant toxicology and toxicokinetics study of SPC-15.

Enliven Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.49) by 16.33 percent. This is a 5.56 percent decrease over losses of $(0.54) per share from the same period last year.

Comments

Amcor

ニュース

最新ニュース Amcor (NYSE:AMCR) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル